Is Juno profitable in 2026?

Juno reported about $85,000 in monthly recurring revenue with 125,000+ patients as of July 4, 2026, per YC's directory, but runs on a two-person team subsidized by a founder-stated $2 million OpenAI compute-credit deal, so profitability post-subsidy is unproven.

Could AI replace Juno?

Juno's entire product is an LLM workflow built on Anthropic Claude and OpenAI compute credits. If OpenAI, Anthropic, or Google ship native health-memory or symptom-tracking features into ChatGPT, Claude, or Gemini, Juno's core conversational loop could be replicated by the very labs it depends on.

How many users does Juno have?

Juno reported 150,000+ patients supported globally with about 70% month-on-month growth as of July 8, 2026, per UCL's accelerator announcement, up from 80,000 users at its May 21, 2026 YC launch post.

Who owns Juno, the chronic-illness AI app?

Juno is a private company backed by Y Combinator's Spring 2026 batch under YC's standard $500,000 for 7% equity terms, per UCL's July 8, 2026 announcement. No independent press report of a priced seed round or outside institutional investors was found as of July 2026.

What is Juno's biggest competitor?

Founders themselves cite general-purpose chatbots like ChatGPT and Claude as the 'default' competitor Juno aims to beat, per its May 21, 2026 YC launch post. Structurally, the bigger threat is the frontier labs Juno depends on shipping native health-memory features.

How does Juno make money?

Juno is free to download with in-app monetization implied by its reported MRR figures; no confirmed pricing tiers were found from a primary source as of July 25, 2026, and its free tier is reportedly subsidized by a founder-stated $2 million OpenAI compute-credit deal.

YC Spring 2026 · United States

Juno

Chat app that helps chronic illness patients track symptoms and patterns using AI.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: OpenAI's $2M compute-credit subsidy for Juno's free tier runs out

The call

Juno has real users and real founder-market fit but no clinical data, EHR ties, or paid retention proven yet, all riding on Claude and GPT credits that expire.

Juno is a smartphone app that uses artificial intelligence to help people with ongoing health conditions track symptoms and get personalized advice. Right now it feels easy for other companies to copy because Juno is built entirely on top of ChatGPT and Claude (the AI services from OpenAI and Anthropic), and those same big tech companies could add the same features directly into their own apps tomorrow. The one thing that could save Juno is if patients become so loyal to its community and the personalized health information it collects about them that they refuse to switch, even if a free option appears in ChatGPT; but the company has not yet proven that patients will actually pay for it once the free trial period ends.

Why

AI pressure: OpenAI, Anthropic, Google (frontier labs building native health memory into ChatGPT/Claude/Gemini). Juno runs entirely on rented Claude and GPT compute; if those labs add symptom memory to their own apps, Juno's core loop gets replicated for free. Could AI do the core job? Yes, likely.

Bigger players: OpenAI, Anthropic, Google. These labs already sell HIPAA-compliant health APIs to enterprises, so adding patient-facing symptom tracking is a feature ship, not a new company. Could a giant copy it? Yes, easily.

What protects it. Founders' own chronic illness history and rare-disease community roots give patient trust a generic chatbot can't fake, at least for now.

What would change this call

OpenAI, Anthropic, or Google ships continuous health-memory or symptom-tracking with HIPAA BAA in a consumer app tier. Shows Juno's core product loop can be replicated inside a mainstream chat assistant.
Juno's reported $2M OpenAI compute-credit deal expires and paid-tier retention/ARPU figures are disclosed. Reveals whether users pay once the subsidy ends or usage was propped up by free compute.
Juno announces a priced seed round or clinical/EHR integration within 12 months. Indicates whether investors and clinics see durable lock-in beyond a thin LLM wrapper.

Key numbers

150,000+ patients served, ~70% month-on-month growth (2026-07-08)
$85,000 MRR reported in YC directory (2026-07-05)
20,000 daily active users run by a 2-person team (2026-07-21)

Named risks

Entire product built on rented Claude and OpenAI compute, exposing Juno to its own suppliers shipping competing features. Severity: high
Only 2 employees supporting 100,000+ signups and 20,000 DAU as of July 2026 risks operational and support strain. Severity: medium
Founder-stated $2M OpenAI compute-credit deal is unverified beyond a single podcast source and may not recur. Severity: medium
No disclosed FDA clearance or clinical/payer partnerships limits path to clinical-grade differentiation. Severity: medium
EU AI Act high-risk health-AI obligations phase in through August 2026 to 2027, raising compliance costs for health-AI apps generally. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
OpenAI, Anthropic, Google (frontier labs)	losing to	Juno's Claude+OpenAI-built product could be replicated if labs ship native health-memory features, 2026
ChatGPT/Claude (general chatbots)	contesting	Founders cite general chatbots as the default alternative Juno aims to beat, May 21, 2026
Aidy (YC W2024)	contesting	Direct YC-backed peer targeting IBD symptom tracking, noted July 22, 2026
Bearable (est. 2019)	gaining on	Bearable lacks an AI conversational layer and has an unresolved web UX gap per April 14, 2026 benchmarking

Questions people ask

Is Juno profitable in 2026?: Juno reported about $85,000 in monthly recurring revenue with 125,000+ patients as of July 4, 2026, per YC's directory, but runs on a two-person team subsidized by a founder-stated $2 million OpenAI compute-credit deal, so profitability post-subsidy is unproven.
Could AI replace Juno?: Juno's entire product is an LLM workflow built on Anthropic Claude and OpenAI compute credits. If OpenAI, Anthropic, or Google ship native health-memory or symptom-tracking features into ChatGPT, Claude, or Gemini, Juno's core conversational loop could be replicated by the very labs it depends on.
How many users does Juno have?: Juno reported 150,000+ patients supported globally with about 70% month-on-month growth as of July 8, 2026, per UCL's accelerator announcement, up from 80,000 users at its May 21, 2026 YC launch post.
Who owns Juno, the chronic-illness AI app?: Juno is a private company backed by Y Combinator's Spring 2026 batch under YC's standard $500,000 for 7% equity terms, per UCL's July 8, 2026 announcement. No independent press report of a priced seed round or outside institutional investors was found as of July 2026.
What is Juno's biggest competitor?: Founders themselves cite general-purpose chatbots like ChatGPT and Claude as the 'default' competitor Juno aims to beat, per its May 21, 2026 YC launch post. Structurally, the bigger threat is the frontier labs Juno depends on shipping native health-memory features.
How does Juno make money?: Juno is free to download with in-app monetization implied by its reported MRR figures; no confirmed pricing tiers were found from a primary source as of July 25, 2026, and its free tier is reportedly subsidized by a founder-stated $2 million OpenAI compute-credit deal.

Timeline

2026-07-22YC directory lists Juno at 2 employees despite 100,000+ signups
2026-07-21Founder states $2M OpenAI compute-credit deal and ~20,000 DAU on podcast
2026-07-08UCL reports 150,000+ patients, ~70% MoM growth, Juno joins YC Spring 2026 batch
2026-07-04YC directory snapshot shows 125,000+ patients and $85K MRR
2026-06Anthropic case study cites 100,000 users and 10% retention lift from Claude onboarding
2026-05-21YC Launch post reports 80,000 users, 9,000+ five-star App Store reviews
2025-10Juno launches publicly

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Trellis Surtr Defense Systems HeyClicky